Market closed
Amgen/AMGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Ticker
AMGN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
26,700
Website
Amgen Metrics
BasicAdvanced
$170B
Market cap
54.43
P/E ratio
$5.80
EPS
0.58
Beta
$8.88
Dividend rate
2.85%
Dividend yield
Price and volume
Market cap
$170B
Beta
0.58
52-week high
$346.85
52-week low
$249.70
Average daily volume
1.9M
Dividend rate
$8.88
Financial strength
Current ratio
1.264
Quick ratio
0.755
Long term debt to equity
964
Total debt to equity
1,057.3
Dividend payout ratio (TTM)
145.56%
Interest coverage (TTM)
2.50%
Management effectiveness
Return on assets (TTM)
6.06%
Return on equity (TTM)
49.27%
Valuation
Price to earnings (TTM)
54.433
Price to revenue (TTM)
5.475
Price to book
28.61
Price to tangible book (TTM)
-3.96
Price to free cash flow (TTM)
30.901
Dividend yield (TTM)
2.81%
Forward dividend yield
2.85%
Growth
Revenue change (TTM)
16.37%
Earnings per share change (TTM)
-60.93%
3-year revenue growth (CAGR)
6.67%
3-year earnings per share growth (CAGR)
-16.21%
3-year dividend per share growth (CAGR)
9.24%
What the Analysts think about Amgen
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Amgen stock.
Amgen Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Amgen Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Amgen News
AllArticlesVideos
Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List
Seeking Alpha·1 day ago
Denosumab (Prolia & Xgeva) by Amgen Biosimilars Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
GlobeNewsWire·2 days ago
Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case
Reuters·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Amgen stock?
Amgen (AMGN) has a market cap of $170B as of October 26, 2024.
What is the P/E ratio for Amgen stock?
The price to earnings (P/E) ratio for Amgen (AMGN) stock is 54.43 as of October 26, 2024.
Does Amgen stock pay dividends?
Yes, the Amgen (AMGN) stock pays dividends to shareholders. As of October 26, 2024, the dividend rate is $8.88 and the yield is 2.85%. Amgen has a payout ratio of 145.56% on a trailing twelve-month basis.
When is the next Amgen dividend payment date?
The next Amgen (AMGN) dividend payment date is unconfirmed.
What is the beta indicator for Amgen?
Amgen (AMGN) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.